Fig. 2

UBE2S affects the expression of TRAF6 protein and the activity of MAPK and PI3K/AKT pathways. (A) RNA sequencing and differentially expression gene enrichment analysis on RKO cells with UBE2S knockdown; (B) Protein analysis with UBE2S knockdown or overexpression; (C) Statistical analysis of UBE2S, TRAF6, p-AKT, and p-ERK protein expression in colorectal cancer and adjacent tissues (n = 3); (D) Statistical analysis of UBE2S and TRAF6 mRNA expression (n = 3); (E) Immunohistochemical quantification scores for colorectal cancer and adjacent tissues (n = 3, 400×); (F) CCK8 proliferation experiment with UBE2S knockdown, adding MAPK inhibitor U0126, PI3K/AKT inhibitor Ipataserib or both inhibitors together (n = 3); (G) Colony formation assays with UBE2S knockdown, adding MAPK inhibitor U0126, PI3K/AKT inhibitor Ipataserib or both inhibitors together (n = 3). ‘*’ represents comparison with adjacent cancer tissues or ‘NC’ group, and ‘#’ represents comparison with the ‘SH’ group. * P < 0.05, **P < 0.01, ***P < 0.001;#P < 0.05, ##P < 0.01, ###P < 0.001, #### P < 0.0001.